Table 3. Univariable and a priori multivariable Cox proportional analysis with DFS as endpoint.
| Variable | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | ||
| Age (years) | 1.00 (0.99–1.01) | 0.6 | 1.00 (0.99–1.02) | 0.9 | |
| Gender male/female (n) | 1.16 (0.85–1.60) | 0.4 | 0.86 (0.55–1.35) | 0.8 | |
| Rectum vs. colon | 1.24 (0.73–1.21) | 0.4 | 2.22 (0.95–5.00) | 0.07 | |
| Neoadjuvant treatment | 0.98 (0.70–1.35) | 0.9 | 0.96 (0.61–1.50) | 0.8 | |
| Node positive disease primary | 1.10 (0.74–1.65) | 0.6 | 0.89 (0.54–1.47) | 0.6 | |
| PCI | 1.05 (1.03–1.07) | <0.001 | 1.03 (1.01–1.06) | 0.005 | |
| Liver metastases | 1.32 (0.79–2.19) | 0.3 | 2.29 (1.25–4.19) | 0.008 | |
| Adjuvant chemotherapy given | 1.20 (0.83–1.73) | 0.3 | 1.24 (0.79–1.92) | 0.3 | |
| CC score 1–3 vs. 0 | 4.18 (2.33–7.52) | <0.001 | 5.19 (2.46–11.0) | <0.001 | |
| HIPEC regimen | |||||
| OX-HIPEC | Reference | ||||
| OX-HIPEC + 5-FU EPIC | 0.76 (0.44–1.31) | 0.3 | 0.48 (0.25–0.92) | 0.03 | |
| OXIRI-HIPEC | 0.66 (0.43–1.01) | 0.06 | 0.59 (0.37–0.94) | 0.03 | |
DFS, disease-free survival; CI, peritoneal cancer index; CC, completeness of cytoreduction; HIPEC, hyperthermic intraperitoneal chemotherapy; OX-HIPEC, oxaliplatin-based HIPEC; 5-FU, 5-fluorouracil; EPIC, post-operative intraperitoneal chemotherapy; OXIRI-HIPEC, oxaliplatin-irinotecan-based HIPEC.